3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-yl trifluoromethanesulfonate | 551920-28-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-yl trifluoromethanesulfonate
• 英文别名: [3-[2-(cyclopropylamino)pyrimidin-4-yl]pyrazolo[1,5-b]pyridazin-6-yl] trifluoromethanesulfonate
• CAS: 551920-28-6
• 化学式: C₁₄H₁₁F₃N₆O₃S
• 分子量: 400.341
• InChiKey: PGFMVPZMGVTWMA-UHFFFAOYSA-N

物化性质

• 密度：
  1.82±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-yl trifluoromethanesulfonate 、 苯硫酚 在 四(三苯基膦)钯 sodium t-butanolate 作用下， 以 二甲基亚砜 为溶剂， 反应 2.0h， 以36%的产率得到N-cyclopropyl-4-[6-(phenylsulfanyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine
  参考文献：
  名称：

  [EN] PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS
  [FR] COMPOSES DE PYRADAZINE UTILES COMME INHIBITEURS DE GSK-3

  摘要：

  本发明通常涉及激酶抑制剂，如GSK3，更具体地涉及根据式(I)的融合吡啶并嘧啶化合物及其使用方法。

  公开号：

  WO2004035588A1
• 作为产物：
  描述：

  N-苯基双(三氟甲烷磺酰)亚胺 、 3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-ol 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以85%的产率得到3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-yl trifluoromethanesulfonate
  参考文献：
  名称：

  Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors

  摘要：

  A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta.

  DOI：

  10.1016/j.bmcl.2008.09.069

文献信息

• [EN] PYRAZOLOPARIDAZINE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLOPARIDAZINE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003051886A1

  公开（公告）日：2003-06-26

  Fused pyradazine derivatives, which are useful as CDK inhibitors are described herein. The described invention also includes methods of making such fused pyradazines derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了作为CDK抑制剂有用的融合吡嗪衍生物。所述发明还包括制备这种融合吡嗪衍生物的方法，以及将其用于治疗增生性疾病的方法。
• Pyradazine compounds as gsk-3 inhibitors
  申请人：Dickerson Howard Scott

  公开号：US20060069097A1

  公开（公告）日：2006-03-30

  The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use.

  本发明通常涉及抑制激酶的抑制剂，例如GSK3，更具体地涉及融合嘧啶二氮杂环化合物及其使用方法。
• Pyrazolopyridazine derivatives
  申请人：SmithKline Beecham Corporation

  公开号：US07279473B2

  公开（公告）日：2007-10-09

  Fused pyradazine derivatives which are usefule as CDK inhibitors are described herein. The described invention alos includes methods of making such fused pyradazine derivatives as wells as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了可用作CDK抑制剂的融合吡啶并咪唑衍生物。所述发明还包括制备这种融合吡啶并咪唑衍生物的方法，以及将其用于治疗增殖过度性疾病的方法。
• Pyradazine compounds as GSK-3 inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US07582630B2

  公开（公告）日：2009-09-01

  The present invention relates to pyrazaolpyradazine derivatives that inhibit GSK3 (glycogen synthase kinase), pharmaceutical compositions containing these derivatives, and methods for their use in the treatment of disorder characterized by misregulation of GSK3.

  本发明涉及抑制GSK3（糖原合成酶激酶）的吡唑吡嗪衍生物，含有这些衍生物的制药组合物，以及将其用于治疗GSK3调节失调性疾病的方法。
• Pyrazolopyridazine derivatves
  申请人：Badiang G Jennifer

  公开号：US20050090507A1

  公开（公告）日：2005-04-28

  Fused pyradazine derivatives, which are useful as CDK inhibitors are described herein. The described invention also includes methods of making such fused pyradazines derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了可用作 CDK 抑制剂的融合哒嗪衍生物。所描述的发明还包括制造这种融合哒嗪衍生物的方法，以及将其用于治疗过度增殖性疾病的方法。